Scott Davies Sells Shares of Illumina, Inc.
Illumina's Chief Legal Officer, Scott Davies, sold 615 shares on June 25, 2026.
Key Points
- Scott Davies, Chief Legal Officer at Illumina, Inc., sold 615 shares on June 25, 2026, for $110,700 under a planned sale.
- Shares of Illumina, Inc. traded near $175.09 on Friday, with a market cap of $24.42 billion and a P/E ratio of 29.29.
- Analysts have mixed ratings on Illumina, with Barclays maintaining a 'sell' rating and JP Morgan upgrading to 'buy' in June 2026.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Scott Davies, the Chief Legal Officer at Illumina, Inc., sold 615 shares of the company on June 25, 2026. The shares were sold at an average price of $180 each, totaling $110,700. This transaction was conducted under a pre-planned trading arrangement, known as a Rule 10b5-1 plan.
Insider Buying and Selling at Illumina, Inc.
In addition to Scott Davies' recent sale, other insiders have also been active. On June 16, 2026, Daniel Skovronsky purchased 1,674 shares at an average price of $164.28. Patricia Leckman, the Senior Vice President and Chief People Officer, sold shares twice in June, with transactions on June 5 and June 2, both under planned sales.
Illumina, Inc. Stock Down 17.6%
Shares of NasdaqGS:ILMN traded around $175.09 on Friday. Illumina, Inc. has a market capitalization of approximately $24.42 billion. The company's price-to-earnings (P/E) ratio is 29.29, with a forward P/E of 27.20. The stock has experienced a 52-week range of $88.00 to $177.22. It has a beta of 1.49, indicating a higher volatility compared to the market.
$ILMN stock price
Daily closing prices, year to date. Not investment advice.
Analysts Set New Price Targets
On June 24, 2026, Barclays maintained a 'sell' rating on Illumina with a price target of $145. Earlier in the month, on June 10, JP Morgan upgraded its rating to 'buy' with a target of $185. Guggenheim also maintained a 'buy' rating with a target of $180 on June 1. Overall, the consensus among analysts is a 'buy' rating, with a mean price target of $148.56 based on 18 analyst opinions.
About Illumina, Inc.
Illumina, Inc., headquartered in San Diego, California, is a leading company in the diagnostics and research industry. It provides sequencing and array-based solutions for genetic and genomic analysis. The company serves a diverse range of customers, including research centers, academic institutions, and healthcare providers. Under the leadership of CEO Jacob Thaysen, Illumina employs approximately 8,600 people and continues to innovate in the field of genomics.
Bottom Line
Scott Davies' recent sale of shares at Illumina, Inc. is part of a planned trading strategy, reflecting routine insider activity. Investors often watch insider transactions for potential insights, though they are not inherently indicative of company performance. Illumina remains a significant player in the genomics field, with varied analyst opinions and a strong market presence.
Get Illumina, Inc. alerts
New 13F filings, insider trades, and analyst moves on $ILMN, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.